Pharmaceuticals Search Engine [selected websites]

Loading

Monday, April 18, 2011

QUANTUM GENOMICS : POSITIVE SCIENTIFIC RESULTS WITH ITS PRODUCT QGC001

Quantum Genomics
01-04-2011 - Quantum Genomics (NYSE Euronext Paris: MLQGC) announced excellent results from regulatory preclinical studies conducted with the product QGC001, the first drug-candidate of a new class of central anti-hypertensive agents, brain aminopeptidase A inhibitors (BAPAI)

  • Anti-hypertensive activity of QGC001 after oral administration has been demonstrated in spontaneously hypertensive rats and conscious hypertensive DOCA-salt rats

  • Toxicology, safety pharmacology and pharmacokinetics studies have demonstrated that QGC001 is well tolerated both in rats and dogs at doses superior to 50 times the dose showing anti-hypertensive activity in rats and has a good bioavailability in dog.

Quantum Genomics plans to submit to AFSSAPS in the following weeks, a clinical trial application in order to initiate a single ascending dose (SAD) study in healthy male volunteer subjects and assess the tolerability of a single dose of QGC001 and its pharmacokinetics parameters in humans... Quantum Genomics' Press Release -

About Quantum Genomics

Quantum Genomics Corp.(QGC) is a global Biotechnology company maximizing the developments and discoveries of academic research into breakthrough treatments for human disease.

QGC has unique expertise in the detection and selection of highly promising life science technology projects.

QGC co-develops products with academic teams, premier Biotech research entities, and some of the world's leading pharmaceutical and bio-science companies.

QGC's strategic alliances and business partnerships range from disease-oriented therapeutic collaborations, technology transfer-agreements, and marketing/licensing agreements, in the fields of recombinant proteins, monoclonal antibodies, and advanced chemical compounds.

QGC develops public/private partnerships to expedite the process of translational research and development, evolving life-science research into market products and therapies. About Quantum Genomics.

Monday, April 11, 2011

CIT : LeadScreen(TM), a new range of fast, cost-effective services for drug candidate selection

citMarch 29, 2011 - CIT, a leading European non-clinical CRO specialized in health and safety research, announces a new range of fast and economical services to meet the growing needs of companies developing the drugs of tomorrow. The services, grouped under the name LeadScreen™, offer an extensive array of tests designed to give an early evaluation of safety of drugs thought to have development potential.
Currently, around 20 per cent of candidate drugs fail during standard regulatory nonclinical studies, too often due to late identification of toxicological effects. Using CIT’s LeadScreen™, the early detection of potential toxicity can significantly increase the chances of success when the candidate drug goes through the later stages of non-clinical development. The speed, competitive price and efficacy of LeadScreen™ offers the ability to reduce considerably the financial cost and time associated with standard drug development practices.
The new LeadScreen™ services are fast. From the start of the study to delivery of the results takes only 14 days - a real competitive advantage over tests currently on the market. As well as saving time, LeadScreen™ presents other advantages such as its requirement for only a small quantity of the compound - and attractive pricing...

[...]

...About CIT

CIT is a science-driven, independent, non-clinical contract research organization (CRO) specialized in safety and health research. Founded in 1969, CIT has carried out a vast number of projects for international companies on human and veterinary pharmaceuticals, biotechnology, chemicals, agrochemicals and consumer products. It has contributed to many product registrations around the world. With a staff of 360, CIT offers a full range of research in general toxicology, reproductive toxicology, carcinogenicity, pharmacokinetics and safety pharmacology... [PDF] CIT's Press Release - PDF du communiqué de presse CIT -

Tuesday, April 5, 2011

IN CELL ART teams up with WAKO for the Japanese commercialization of IN CELL ART’s breakthrough ICAFectin441 and ICAFectin442 transfection reagents

IN CELL ARTNantes – France, January 18, 2011 – IN CELL ART, a leading company in nucleic acids (DNA, siRNA) delivery systems announces that the company has entered into a distribution agreement with WAKO, a leading supplier of products and reagents.
Under the terms of this agreement, IN CELL ART and WAKO partner for the marketing, distribution and sales of IN CELL ART’s novel synthetic derivatives of natural compounds, ICAFectin®441 and ICAFectin®442, designed for high DNA and siRNA transfection efficiency.
WAKO’s customers have now access to reagents among the most performing of the market for high efficiency DNA and siRNA delivery in primary and stem cells.
“This alliance is of crucial importance as WAKO brings a vast knowledge of the Japanese transfection reagents market together with a highly organized distribution network that gives to IN CELL ART the opportunity to strengthen and enlarge its products distribution channels”, explain Chloé Bellocq, CEO and Bruno Pitard, scientific adviser and co-founder of IN CELL ART...

[...]

...About IN-CELL-ART

IN CELL ART, which is headquartered in Nantes (France) is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of nanocarriers for macromolecular drugs. Its founder and research team, which includes a Nobel Laureate, have designed new classes of vectors that are organized on a nanometric scale, which enables them to cross the cell barrier efficiently and safely... [PDF] IN-CELL-ART's Press Release - PDF du communiqué de presse IN-CELL-ART -